The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors

Cancer Immunology, Immunotherapy

Volumn 50, Issue 6, 2001, Pages 321-327

  Yoshida, Seiichi ^a   Morii, Ken ^a   Watanabe, Masato ^a   Saito, Takashi ^a   Yamamoto, Kiyoshi ^b   Tanaka, Ryuichi ^b  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Dendritic cells; Glioma; Immunotherapy; Malignant brain tumors

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CHROMIUM 51;

ANTIGEN SPECIFICITY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG ADENOCARCINOMA; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ASTROCYTOMA; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034887334     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100201     Document Type: Article

References (37)

1. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
2. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
3. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
4. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
5. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
6. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology and results
7. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation
8. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
9. Role of bone marrow-derived cell in presenting MHC class I-restricted tumor antigens
10. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations
11. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
12. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells
13. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
14. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
15. Induction of antigen specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
16. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
17. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
18. Induction of antitumor immunity using bone marrow-generated dendritic cells
19. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients
20. + T-helper and a T-killer cell
21. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
22. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system
23. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage-colony-stimulating factor GM-CSF plus interleukin-4 and down-regulated by tumor necrosis factor α
24. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system
25. Dendritic cells as adjuvants for immune-mediated resistance to tumor
26. Randomized trial of three chemotherapy regimens in postoperative treatment of malignant glioma
27. Culture of established, intracereberal rat glioma induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN gamma treatment
28. Studies of the adjuvant-independent antibody response to immunotargeting: Target structure dependence, isotype distribution, and induction of long term memory
29. Tumor antigens and tumor vaccines: Peptides as immunogens
30. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo
31. The dendritic cell system and its role in immunogenicity
32. + human blood dendritic cells for active tumor immunotherapy
33. Biological properties of dendritic cells: Implications to their use in the treatment of cancer
34. Isolation and function of human dendritic cells
35. Dendritic cells as adjuvants for class 1 major histocompatibility complex-restricted anti-tumor immunity
36. Accessory cell requirements for the mixed leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells
37. Therapy of murine tumors with tumor peptides-pulsed dendritic cells: Dependency on T cells, B7 costimulation, and T helper cell I-associated cytokines